RxSight Third Quarter 2026 Earnings Conference Call - RXSIGHT INC

Financial Performance:

• Q3 2026 total revenue was $24.6 million, a 19% year-over-year decline from $30.3 million.
• LAL procedure volume declined 11% year-over-year to 23,128 units, contributing $22.8 million to revenue; remaining revenue came from LDD and services.
• Gross margin contracted to 73.6% from 79.9% in the prior year period, primarily due to increased inventory reserves and the sell-through of lower-cost inventory in the prior year.
• SG&A expenses were $27.4 million (flat year-over-year); R&D was $9.2 million (consistent with prior year).
• Net loss was $16.2 million ($0.39/share); adjusted net loss was $8.6 million ($0.21/share) after $7.6 million in stock-based compensation.
• Cash, cash equivalents, and short-term investments totaled $254.7 million, including a $60 million upfront payment from the Alcon collaboration.

Guidance and Future Outlook:

• Company is not providing formal full-year 2026 financial guidance.
• Formal 2027 guidance (revenue, OPEX, and milestone-related) is expected to be provided following the Q4 2026 earnings release in early 2027.
• Management anticipates Q4 LAL revenue to trend in line with Q2 levels (mid-to-high single-digit sequential growth), despite Q3 seasonality and ongoing restructuring.
• Long-term goal is to achieve lower total OPEX in 2027 compared to 2026, even while incrementally increasing investment in the sales force, Alcon partnership, and next-generation pipeline.
• Next-generation LAL platform is on track for an earliest potential approval in 2028.

Business Segments and Product Lines:

• LAL (Light Adjustable Lens): Primary strategic focus; strategy shifted to driving utilization within the existing install base rather than acquiring new surgeons.
• Commercial Leadership: Appointed Taryn Conway as Chief Commercial Officer and Frank Shields as EVP of Sales and Commercial Strategy.
• Sales Force: Nearly doubled U.S. Salesforce team size to increase engagement frequency and support better practice integration.
• LDD (Light Adjustable Delivery Device): Sales are expected to remain limited and strategic, with resources reallocated from LDD to LAL utilization. ASPs for LDD remained stable.
• Alcon Collaboration: Passed the initial 120-day milestone, securing upfront payments and solidifying the partnership to potentially bring adjustability to the broader premium IOL market.
• Next-Gen Pipeline: Focusing on expanding patient eligibility, reducing clinical workflow visits, and improving surgical design/ergonomics.

Market and Competitive Landscape:

• Facing continued competitive pressure from new IOL launches (e.g., J&J PureSight EDOF) offering "trialing" via free product samples, which impacts near-term utilization.
• Management asserts that while competitors offer modest improvements, LAL remains superior in delivering spectacle-free outcomes and personalized vision, particularly for post-refractive patients.
• Market surgical volume has stabilized since early 2026 but remains "slightly soft."
• Physician feedback at the American Academy of Ophthalmology meeting indicates strong continued enthusiasm for adjustability and LAL outcomes.
• LAL retains a strong "moat" in the post-refractive segment, though some trialing of alternative lenses in lower-risk cases is occurring.

Risks and Challenges:

• Competitive Disruption: Free product samples from competitors are cannibalizing trial and utilization rates.
• Internal Disruption: Recent Salesforce expansion, territory remapping, and organizational restructuring have caused temporary near-term friction and reduced field presence.
• Seasonality: Q3 is historically softer due to holiday periods.
• Execution Risk: Need to successfully translate "pocket of strength" successes in top-performing clinics to the broader physician base.

Management Commentary and Tone:

• Tone is cautious but confident in the technology and long-term strategy; acknowledges "near-term pain" to achieve long-term value.
• CEO Aziz Motiwala emphasizes passion for the technology, a clear three-part strategic focus (U.S. LAL, Next-Gen, Alcon), and the importance of operating discipline.
• Management acknowledges that the transition to a larger sales team and restructuring has temporarily impacted performance but views this as necessary for future scalability.
• Strong emphasis on "frequency" of engagement and practice workflow integration as key differentiators to secure long-term growth.

Analyst Questions and Answers:

• Yoy Decline Drivers: Aziz attributed Q3 decline to a compounding effect of seasonality, competitive pressure (free product trials), and internal disruption from restructuring.
• Q4 Outlook: Mark confirmed Q4 revenue guidance will likely mirror Q2 performance, driven by lack of Q3 seasonality and October trends.
• International Strategy: International operations remain a lower priority compared to U.S. LAL reinvigoration, next-gen development, and the Alcon partnership.
• Pockets of Strength: High-performing accounts attribute success to higher sales team frequency and deep practice workflow integration; management plans to replicate this model broadly.
• LDD Strategy: LDD will see significantly reduced sales volume as resources pivot to LAL; ASPs remain stable.
• Competitive Moat: While some competitors are trialing post-refractive cases, management does not anticipate a wholesale shift away from LAL for this patient segment.
• Operating Rigor: New focus on data-driven KPIs, customer segmentation, and capital allocation discipline to drive OPEX reduction in 2027.

Other Key Points:

• The $60 million Alcon upfront payment is now fully recognized on the balance sheet.
• Restructuring actions included changes to manufacturing, corporate functions, and international operations, expected to generate meaningful savings by 2027.
• Management highlighted the importance of educating the entire practice staff, not just the surgeon, to drive workflow efficiency and utilization.
• No major product recalls or significant regulatory hurdles were mentioned during the call.